Fig. 5
From: Identification of STEAP3-based molecular subtype and risk model in ovarian cancer
Analysis of immune landscape and chemotherapy sensitivity in different risk groups. (A) Comparisons of immune cell infiltration between two risk groups. (B) Differences of immune, stromal and ESTIMATE scores of high- and low-risk groups. (C) Relationship between the risk score and molecular subtypes. (D) Differences of TIDE, T cell dysfunction and T cell exclusion scores in distinct risk groups. (E) Distributions of non-responder and responder to immunotherapy between different risk groups. (F) Differences of chemotherapy sensitivity between two risk groups. *p < 0.05; **p < 0.01; ***p < 0.001